Free Trial

Haleon (HLN) Stock Forecast & Price Target

Haleon logo
GBX 360 -2.30 (-0.63%)
As of 12:05 PM Eastern

Haleon - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
1
Hold
1
Buy
1

Based on 3 Wall Street analysts who have issued ratings for Haleon in the last 12 months, the stock has a consensus rating of "Hold." Out of the 3 analysts, 1 has given a sell rating, 1 has given a hold rating, and 1 has given a buy rating for HLN.

Consensus Price Target

GBX 435
According to the 3 analysts' twelve-month price targets for Haleon, the average price target is GBX 435. The highest price target for HLN is GBX 500, while the lowest price target for HLN is GBX 370. The average price target represents a forecasted upside of 20.83% from the current price of GBX 360.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for HLN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Haleon and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

HLN Analyst Ratings Over Time

TypeCurrent Forecast
8/28/24 to 8/28/25
1 Month Ago
7/29/24 to 7/29/25
3 Months Ago
5/30/24 to 5/30/25
1 Year Ago
8/29/23 to 8/28/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
3 Buy rating(s)
Hold
1 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
1 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price TargetGBX 435GBX 457GBX 457GBX 367.50
Consensus Rating
Hold
Buy
Buy
Moderate Buy

HLN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

HLN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Haleon Stock vs. The Competition

TypeHaleonMedical Companies
Consensus Rating Score
2.00
2.78
Consensus RatingHoldModerate Buy
News Sentiment Rating
Positive News

See Recent HLN News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/8/2025Berenberg Bank
2 of 5 stars
 Lower TargetBuyGBX 503 ➝ GBX 500+41.08%
8/1/2025JPMorgan Chase & Co.
2 of 5 stars
 Reiterated RatingUnderweight
7/31/2025Royal Bank Of Canada
3 of 5 stars
 Reiterated RatingSector performGBX 370+1.12%
4/18/2024HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy
4/9/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweightGBX 390 ➝ GBX 383+19.28%
10/11/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetGBX 340 ➝ GBX 360+6.82%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 04:39 PM ET.


Should I Buy Haleon Stock? HLN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, August 27, 2025. Please send any questions or comments about these Haleon pros and cons to contact@marketbeat.com.

Haleon
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Haleon plc:

  • The current stock price is around $4.65, which may present a buying opportunity for investors looking for value in the consumer health sector.
  • Haleon plc reported a solid earnings per share (EPS) of $0.12 for the latest quarter, indicating profitability and potential for future growth.
  • The company has a return on equity of 6.54%, suggesting effective management and the ability to generate profits from shareholders' equity.
  • With a market capitalization of approximately £31.57 billion, Haleon plc is positioned as a significant player in the consumer health market, which can attract institutional investors.
  • Insider activity shows confidence in the company, with insiders owning 10.74% of the stock, indicating that those with the most knowledge of the company are investing in it.

Haleon
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Haleon plc for these reasons:

  • The stock has experienced volatility, with a 1-year high of $5.58 and a low of $4.60, which may indicate uncertainty in its price stability.
  • Haleon plc has a relatively high price-to-earnings (P/E) ratio of 29.42, suggesting that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
  • The company has a debt-to-equity ratio of 53.36, indicating a higher level of debt compared to equity, which could pose risks in times of economic downturns.
  • Recent analyst ratings include a "sector perform" rating, which suggests that the stock may not outperform the market, potentially limiting upside for investors.
  • Market conditions and competition in the consumer health sector could impact Haleon plc's growth prospects, making it a riskier investment choice.

HLN Forecast - Frequently Asked Questions

According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for Haleon is GBX 435, with a high forecast of GBX 500 and a low forecast of GBX 370.

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Haleon in the last year. There is currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" HLN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HLN, but not buy additional shares or sell existing shares.

According to analysts, Haleon's stock has a predicted upside of 20.83% based on their 12-month stock forecasts.

Haleon has been rated by research analysts at Berenberg Bank, JPMorgan Chase & Co., and Royal Bank Of Canada in the past 90 days.

Analysts like Haleon less than other "medical" companies. The consensus rating for Haleon is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how HLN compares to other companies.


This page (LON:HLN) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners